SK pharmteco Launches SKyvec Proprietary Multimodal Viral Vector Platform

Why This Matters: Check out all our BIO 2026 coverage here.

SK pharmteco is launching SKyvec, a proprietary, multimodal viral vector platform designed to support gene therapy programs at multiple stages. The company took the occasion of the BIO International Convention in San Diego to announce the launch.

The platform unites three core modalities, adeno-associated virus (AAV), adenoviral, and lentiviral vectors, under one offering. SK pharmteco says this gives therapeutics developers the flexibility to leverage custom and regulatory-ready solutions meeting their programs’ unique requirements.

Talking with SK pharmteco at BIO

At BIO 2026, Contract Pharma spoke with SK pharmteco’s John Lee, PhD. Lee is a company Vice President and Head of the Cell & Gene Therapy Business Unit.

Lee emphasized that the launch integrates development capabilities between North America and Europe. The platform is available at SK pharmteco’s United States and European facilities.

“It is particularly attractive for those customers who are looking to globalize their therapies,” Lee said.

He added that SK pharmteco, like many other companies right now, is concentrating on harmonizing its standards across multiple continents. That can often be a challenge.

“Different sites have different platform processes that then become difficult to transfer from one geography to another,” Lee said. “It’s not impossible, but it typically slows things down.”

Tech Specs for SKyvec

Breaking down SKyvec’s technical specifications, upstream process development is conducted at scales up to 200 L. This aligns fully with good manufacturing practice (GMP) with scale-up to 500-L and 1000-L bioreactors.

The suspension-based upstream platforms provide maximum scalability, but an adherent AAV platform remains available.

According to Lee, this flexibility supports developers from early research through clinical supply and commercial manufacturing.

“It really gives our customers additional confidence that you can come in low-cost, low-risk, [and] check us out,” he said.